Paramune develops biologic therapies targeting inflammatory diseases and cancer, leveraging discoveries from Stanford University. The company employs next-generation biologic formats to create therapeutic candidates with high efficacy and safety profiles.
Targeting molecular mechanisms in cancer treatment; Developing therapies for autoimmune diseases; Engaging identified targets for therapeutic efficacy; Engineering molecules for safety profiles; Advancing clinical stage development
Founded by expert immunologists from Stanford University; Based in the San Francisco Bay Area; Rapidly growing company with a focus on team-centered culture